AXSM
Axsome Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$216.58
−1.89%Price chart
Aug 13Aug 18Aug 21Aug 26Aug 31Sep 3Sep 9Sep 14
ValuationView details →
P/E (Fwd)
1292.2x
EV/EBITDA
−62.5x
Market Cap
$11.34B
MomentumView details →
1D Return
−1.89%
YTD Return
+21.24%
RSI (14)
59.7
ValuationView details →
P/E (Fwd)
1292.2x
EV/EBITDA
−62.5x
Market Cap
$11.34B
RSI (14)
59.7
MomentumView details →
1D Return
−1.89%
YTD Return
+21.24%
SummaryUpdated Jun 1, 2026
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical company founded in 2012 and headquartered in New York. The company went public in 2015 and focuses on developing and commercializing novel therapies for central nervous system (CNS) disorders. Axsome has successfully transitioned from a pure development-stage company to a commercial-stage biopharmaceutical company with multiple approved products generating significant revenue growth.
Similar companies
Latest newsMore news →
Axsome Therapeutics began dosing in the Phase III SUMMIT study of AXS-05 for smoking cessation in adults.14d agoBlackRock Inc. acquired a new minority stake in Axsome Therapeutics, Inc., buying 3,103,708 shares valued at approximately $759.70 million during the second quarter, as disclosed in its 13F filing with the SEC.23d agoAxsome Therapeutics initiated FOCUS-2 and FOCUS-3 Phase 3 trials of solriamfetol in children and adolescents with ADHD.36d ago